Skip to content

New Harbor Capital Portfolio Company LGM Pharma Completes Acquisition of Sannova Analytical

New Harbor Capital branded teal private equity investments icon private equity news

New Harbor Capital (“New Harbor”) announced today that its portfolio company LGM Pharma (“LGM”), an Active Pharmaceutical Ingredient (“API”) supply chain and analytical testing services business supporting pharmaceutical and pharmacy companies, has acquired Sannova Analytical (“Sannova”, “the Company”), a contract research laboratory headquartered in Somerset, N.J. The acquisition expands LGM Pharma’s capabilities by adding Good Laboratory Practice (“GLP”) bioanalysis, including peptide and oligonucleotide testing, and by bringing genotoxic and nitrosamine impurity testing, as well as extractables and leachables evaluations, to LGM’s existing current Good Manufacturing Practice (“cGMP”) analytical services. This acquisition is the third in partnership with New Harbor and is part of LGM Pharma’s broader strategy to build a scaled U.S.-based analytical services platform alongside its API sourcing business.

Sannova will continue to operate under its own name as Sannova Analytical, led by its current management team. Sannova clients will keep the same scientific team, qualified methods, and contacts they work with today.

Sannova Analytical is an FDA- and DEA-registered contract research laboratory supporting both small and large molecule drug modalities. This strategic acquisition gives clients a single partner for API sourcing, release and stability testing of APIs and drug products, and bioanalysis, whether they are manufacturers working through nitrosamine drug substance-related impurity (“NDSRI”) risk assessments or biotech teams moving a program from preclinical studies through Phase 4.

Sannova also brings expertise in nitrosamine impurity testing to LGM. Additionally, Sannova conducts extractables and leachables evaluations, which identify compounds that can migrate into a drug product from container closure systems, single-use manufacturing components, and delivery devices. The Company has completed over 3,500 cGMP analytical studies, and its laboratory is DEA-registered for Schedules II through V controlled substances.

“Over the last five years, we’ve built analytical testing into a standalone business, and the two things our clients keep asking for are bioanalysis and more extensive impurity work,” said Prasad Raje, Ph.D., CEO of LGM Pharma. “Sannova gives us both, along with a U.S.-based team that develops and validates its methods at the center of the Northeast pharmaceutical corridor. This acquisition provides additional capabilities, but it also adds capacity for the growing volume of work our clients are bringing to us.”

“Our clients chose Sannova for the people and methods behind their data, and those stay in place,” said Malleswar Kollu, President and CEO of Sannova Analytical. “LGM Pharma’s backing lets us continue investing in our scientists, instruments, capacity, and client services faster than we could independently.”

“We are excited to continue building LGM Pharma alongside its experienced management team,” said Tom Formolo, Partner at New Harbor Capital. “Sannova’s specialized capabilities and strong regulatory record in a rapidly growing segment of the market will enable LGM to be an even more valuable partner to its customers.”

Fairmount Partners served as financial advisor and Goodwin Procter served as legal counsel to Sannova Analytical. Reed Smith served as legal counsel to LGM Pharma.

About LGM Pharma

Founded in 2005 and headquartered in Boca Raton, FL, LGM Pharma is a drug development service organization providing active pharmaceutical ingredient (API) sourcing and contract analytical testing to the pharmaceutical, biotechnology, and compounding pharmacy industries. The company helps clients manage every phase of drug development, from early sourcing through commercialization. Its global network of qualified API partners enables clients to enhance supply chain management and distribution. Services include API sourcing and procurement, analytical method development, method and process validation, ANDA and NDA submission, stability studies, and raw material and finished product testing. LGM Pharma is committed to quality and provides expert regulatory and market intelligence services. Its customer-focused, U.S.-based team helps reduce risk, increase efficiency, and accelerate the path to commercialization. For more information, visit LGMPharma.com.

About Sannova Analytical

Founded in 2006 in Somerset, NJ, Sannova Analytical is an FDA- and DEA-registered contract research laboratory supporting both small and large molecule drug modalities. Sannova provides cGMP chemistry, manufacturing and controls (CMC) analytical testing for characterization and release of clinical and commercial material, as well as GLP bioanalytical testing services in support of preclinical animal and clinical human sample analysis. The company serves pharmaceutical, biotechnology, generic drug, and CDMO companies, along with clinical research sites. Its CMC practice includes method development and validation, stability testing, and impurities analysis, with a specialization in nitrosamine and NDSRI testing, as well as extractables and leachables evaluations. Its bioanalytical practice supports pharmacokinetic, toxicokinetic, bioequivalence, and immunogenicity programs, with methods validated in accordance with ICH M10. Sannova’s capabilities span across small molecules, peptides, and oligonucleotides. Sannova is FDA-inspected and audited by its clients. For more information, visit Sannova.com.